83-2272-59　［受注停止］KRIBIOLISA Tepoditamab ELISA 1 x 96 wells　KBI1770

特徴

• Description：ELISA for the detection of bispecific antibody Tepoditamab in human serum and plasma.
• Lead time for this kit is 5 weeks.
• About the kit： - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％ - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life： 1 year.
• Tepoditamab is an IgG1 bispecific human monoclonal antibody against human CD3, a T-cell surface antigen, and human C-type lectin domain family 12 member A, a tumor-associated antigen （TAA） overexpressed on certain tumor cells, with potential antineoplastic activity.
• Tepoditamab binds to both CD3 on T-cells and CLEC12A expressed on malignant cells, such as myeloid blasts, atypical progenitor cells and leukemic stem cells （LSCs）.
• This results in the cross-linking of T-cells with tumor cells, and induces a potent cytotoxic T-lymphocyte （CTL） response against CLEC12A-expressing tumor cells.
• CLEC12A, a myeloid differentiation antigen and member of the C-type lectin/C-type lectin-like domain （CTL/CTLD） superfamily, is overexpressed on myeloid leukemia cells, but not on normal early hematopoietic progenitors, including hematopoietic stem cells （HSCs）.